Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry
Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry.
Clinical Pearls:
IL-2 is an immunotherapy that can give complete responses that last years
The database retrospectively looked back over a 5-year period
The registry showed that IL-2 still gives an occasional, durable response
The registry also showed that clinical factors such as normal LDH and patient performance status is important in determining who will be successful on IL-2
Patients with stable disease or did not seem to respond to IL-2 initially had better overall survival than previously thought, according to the registry findings
